Research Article
Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data
Table 3
Univariate and multivariate Cox proportional hazards analysis for CPEB3 expression.
| Characteristics | Univariate analysis | Multivariate analysis | Hazard ratio (95% CI) | value | Hazard ratio (95% CI) | value |
| T stage (T0-2 vs. T3-4) | 2.056 (1.502-2.814) | <0.001 | 1.177 (0.754-1.836) | 0.474 | N stage (N0 vs. N1-3) | 1.711 (1.271-2.304) | <0.001 | 3.959 (1.152-13.602) | 0.029 | M stage (M0 vs. M1) | 1.734 (0.915-3.287) | 0.092 | 1.507 (0.56-4.056) | 0.417 | Clinical stage (stage 0-II vs. stage III-IV) | 1.579 (1.177-2.118) | 0.002 | 0.546 (0.154-1.935) | 0.348 | Melanoma Clark level (I-III vs. IV-V) | 2.117 (1.472-3.045) | <0.001 | 1.259 (0.771-2.056) | 0.357 | Gender (female vs. male) | 1.164 (0.872-1.554) | 0.301 | | | Age (≤60 vs. >60) | 1.678 (1.266-2.225) | <0.001 | 1.167 (0.785-1.735) | 0.447 | Height (>170 vs. ≤170) | 0.96 (0.625-1.475) | 0.853 | | | Weight (≤80 vs. >80) | 0.853 (0.557-1.307) | 0.466 | | | BMI (≤25 vs. >25) | 0.819 (0.508-1.321) | 0.414 | | | Tumor tissue site (extremities vs. trunk) | 0.941 (0.693-1.278) | 0.698 | | | Melanoma ulceration (no vs. yes) | 2.087 (1.494-2.916) | <0.001 | 1.793 (1.209-2.66) | 0.004 | CPEB3 (low vs. high) | 0.609 (0.464-0.799) | <0.001 | 0.45 (0.305-0.664) | <0.001 |
|
|